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The ABO system is one of the most important
blood group systems in transfusion medicine. The ABO
system consists of A antigens,B antigens,and antibodies
against these antigens. Landsteiner discovered the ABO
system in 1900. As opposed to many other blood group
systems such as the Rh system, in this system the
presence of “naturally occurring” antibodies against A
and B antigens in individuals who do not express those
antigens (Landsteiner’s Law) causes an adverse and
occasionally fatal outcome at the first mismatched
transfusion. The concept that “only matched donor
blood that would not result in RBC agglutination could
be transfused” set the path for safe blood transfusion.
The ABO system is of interest in a variety of
scientific fields (Table 1). In addition to the four major
groups (A, B,AB, and O), we now know that additional
subgroups exist that exhibit different patterns and
degrees of agglutination. The A and B antigens were
initially identified on RBCs, and later they were found
on the surfaces of other types of cells as well as in
secretions. Therefore, the ABO system is occasionally
called the histo-blood group system, rather than the
blood group system. Because these antigens exist in
cells other than RBCs, ABO matching is important not
only in blood transfusion but also in cell, tissue, and
organ transplantation. Forensic science utilizes the
ABO blood groups for suspect exclusion in the analysis
of crime scene evidence, such as blood, saliva, seminal
fluid, and even hair.
The A and B antigens are carbohydrate antigens,
and not protein antigens, the primary gene products.
The A and B antigens are synthesized by a series of
enzymatic reactions catalyzed by enzymes called
glycosyltransferases. The final step of their
biosynthesis is catalyzed by A and B transferases
encoded by the functional A and B alleles at the ABO
genetic locus, respectively. The allele frequencies vary
among different races, which furnishes interesting
questions in population studies, anthropology, and
Table 1 . A wide variety of ABO studies
 ABO Genes
Polymorphic: three major (A, B, and O) and dozens of subgroup
(A2, Ax, B3, etc.) alleles
Different allele frequencies among different races
⇒ genetics, population study, anthropology
 A and B Antigens
Oligosaccharide antigens
⇒ carbohydrate chemistry, glycobiology
RBC, various tissues and cell types, and secretion (saliva, seminal fluid,
etc.)
⇒ blood transfusion, cell/tissue/organ transplantation,
for ensic sciences
Human, chimp (A,O), gorilla (B), baboon (A, B,AB), pig (A,O), etc.
⇒ systematics
Expression changes during development, cell differentiation, and
carcinogenesis
⇒ molecular biology, developmental and cellular biology,
cancer biology
 A and B Glycosyltransferases
Different donor nucleotide-sugar substrate specificity
⇒ enzymology, structural biology
Presence of transferases with similar specificity (α1,3GalT, Forssman
synthase, iGb3 synthase)
⇒ evolution
 Anti-A and Anti-B Antibodies
“Naturally occurring” antibodies
⇒ immunology
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human genetics. A and B antigens are not restricted to
humans. The identical or similar antigens have been
identified in other species. Furthermore, glycosyl-
transferases other than A and B transferases exist that
exhibit similar specificity in reactions. Therefore,ABO
is also of evolutionary and enzymological interest. A/B
antigen expression exhibits dynamic changes during
development and pathogenesis. Loss of A/B antigen
expression in cancer, such as prostate cancer, has been
documented. Therefore, the expression of ABO genes
is an interesting subject in cancer biology in addition to
molecular, cellular, and developmental biology. Safer
blood transfusion conceived by Landsteiner and
improved upon by many others, primarily immuno-
hematologists, has become a routine medical practice.
Since the cloning of the ABO gene in 1990,1 progress
has been made in the structural and functional analyses
of the ABO genes and A and B transferases at the
molecular level. I hope that the readers of
Immunohematology find this review article
interesting and useful for a better understanding of the
scientific basis of the ABO system,oligosaccharide ABH
antigens, A and B transferases, and ABO genes, and for
applying this information to clinical applications.
ABO blood grouping is crucial for safe blood
transfusion.
The discovery of the ABO blood group system was
made when Landsteiner separated the cellular
components from the liquid components of blood and
observed the agglutination of RBCs in certain
combinations upon mixing (Fig. 1). Based on the
agglutination patterns, he categorized the subjects into
three groups. In the next year Decastello and Sturli
discovered the fourth group, and these four groups
became the ABO blood groups. In order to explain the
agglutination patterns, Landsteiner postulated that
there were two antigens (A and B) and two antibodies
against those antigens (anti-A and anti-B). He assumed
the presence of the antibodies in the sera of individuals
who did not express those antigens, which was later
named Landsteiner’s Law. His understanding was an
important step toward the safe practice of blood
transfusion, where transfusion should be performed
between individuals whose blood components would
not agglutinate upon mixing. It was reasonable to
assume that the hemagglutination due to mismatch
would also occur inside the body if it occurs in the test
tube. Therefore,ABO typing before any transfusion was
logical. To crossmatch also was wise because unknown
antigens or antibodies could be present. Because the
readers of Immunohematology are familiar with safe
practice of blood transfusion and the techniques used
for ABO typing, they are not described in detail here.
Please refer to several excellent books on transfusion
medicine for information.2–4 It is important to note that
subgroups have been identified, based on the different
degrees and patterns of agglutination, using reference
RBCs and antibodies. Those subgroups include A2, A3,
Ax, Ael, B3, Bx, and Bel. The natural antibodies seem to
occur due to constant or occasional immunologic
stimulation by substances, such as food, pollen, and
bacteria, that are ubiquitous in nature.
A and B antigens ar e not protein antigens
but oligosacchar ide antigens.
Because the antibodies against A and B antigens
were available from human sera and later from
monoclonal origins, those reagents were used for
immunohistochemistry, in addition to hemagglu-
tination for blood typing. Some plant lectins were
found to have an affinity with A and B antigens and
were used for immunostaining purposes. It soon
became clear that the expression of A and B antigens
was not limited to RBCs. Those antigens were also
found on the surfaces of several different types of
human cells and demonstrated in secretions by an
inhibition test. The antigens reactive to those
antibodies and lectins were also found to be present in
other species of organisms, including bacteria and
plants, although the chemical nature of those antigens
remains to be characterized.
In the 1930s, Landsteiner and colleagues suggested
that soluble substances in secretions that inhibit
hemagglutination were some type of new
carbohydrate-amino acid complex. Later, in the 1950s,
a group led byWatkins and Morgan and another group
led by Kabat played a major role in the final
determination of the chemical nature of ABH
antigenicity (H antigens were found to be abundant in
individuals with group O type blood group). They
initially showed that simple sugars inhibited lectin-
mediated agglutination of RBCs and prevented the
specific precipitation of soluble blood group
substances. This suggested a link between certain
sugars and blood group specificity; N-acetyl-D-
galactosamine,D-galactose, and L-fucose for A, B, and H
specificity, respectively. Watkins and Morgan later
showed that glycosidase preparations from bacteria
and mollusks abolished the antigenicity, confirming the
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Fig. 1 . ABO System. Discovery of the ABO blood groups, antigen-antibody hypothesis of RBC agglutination, chemical nature of A and B antigens and
their biosynthetic pathways are shown.
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importance of those sugars for the blood group
specificity. A more direct approach was taken to purify
A, B, and H determinants from ovarian cysts, which
secrete soluble forms of these antigens in abundance.
The cyst fluid was acid-hydrolyzed and alkaline-
degraded, and the released carbohydrate fragments
were analyzed for binding activity toward anti-A and
anti-B antibodies. These studies revealed that the
immunodominant structures of those antigens are
oligosaccharides.5,6 The structures of the related Lea,
Leb, and Lex substances were also determined. Their







The peripheral disaccharide core structures on
which ABH determinants are synthesized were also







The ABH antigens occur on glycoproteins, on
glycolipids,and as free oligosaccharides. The structures
of membrane-bound ABH antigens on erythrocytes
were later characterized and found to contain the same
immunodominant structures found in the soluble
forms of ABH substances.
A and B glycosyltransferases catalyze the
final step of biosynthesis of A and B
oligosacchar ide antigens.
Once the structures of A, B, H, and related antigens
were determined, the biosynthetic pathways of those
antigens were proposed in due course. Because these
structures are oligosaccharides and cannot be the
primary gene products of proteins, it was assumed that
they were synthesized by the actions of enzymes
encoded by the genes. Watkins and Morgan,7,8 and
separately Ceppellini,9 proposed the following
hypothesis. Functional A and B alleles at the ABO locus
encode A and B glycosyltransferases that catalyze the
addition of an N-acetyl-D-galactosamine and D-
galactose by an α1-3 glycosidic linkage to synthesize
the A and B structures, respectively. This hypothesis
was later supported by the experimental data that
correlated enzyme activities of those transferases and
blood group phenotypes.10,11 A transferase activity was
observed in the tissues and sera that exhibited A
antigens whereas B transferase activity was detected in
the tissues and sera that exhibited B antigens.
A and B genes at the ABO genetic locus
encode A and B glycosyltransferases.
The ABO polymorphism was one of the first
genetic traits in humans that were shown to be
inherited. To explain the mode of inheritance,
Bernstein proposed the one gene locus–three allelic
model (Fig. 1). He assumed that the A, B, and O genes
are alleles at the same ABO genetic locus. He also
assumed that the A and B alleles are co-dominant
against the recessive O allele. Based on the
combinations, six genotypes resulting in four
phenotypes were postulated. In addition to the three
major alleles, additional alleles specifying subgroups
have later been integrated into the scheme. Regarding
the mode of inheritance of ABO, two interesting
phenomena have been reported that are called cis-AB
and B(A). The expression of A and B antigens is
specified by two separate A and B genes (one derived
from the mother and the other derived from the father)
in a common AB phenotype (trans-AB). However, in
rare cases of AB, the expression of both A and (usually
weak) B antigens is inherited by a single gene derived
from either one of the parents, and this phenomenon
was named cis-AB.12,13 A similar phenomenon named
B(A) was reported when weak A reactivity was
demonstrated using certain monoclonal anti-A reagents
with the cases that had been previously diagnosed to
be type B.14 Although the mode of inheritance was not
demonstrated in those cases, it was assumed that small
amounts of A antigens, in addition to larger amounts of
B antigens, were produced by a special B transferase.
This is quite likely because even the regular B
transferase is able to transfer GalNAc to the acceptor
substrate in vitro, although inefficiently, as previously
demonstrated by Greenwell et al.15
The central dogma seemed correct that A and B
genes encode A and B transferases, which synthesize A
and B antigens, respectively, because the correlation
I M M U N O H E M A T O L O G Y, V O L U M E 2 0 , N U M B E R 1 , 2 0 0 4 7
Review:ABO blood group system
was established between the ABO phenotypes and the
presence or absence of A and B transferase activity.
However, conclusive proof had to wait for the cloning
of the ABO genes.
A and B genes encode A and B transferases
of differ ent sugar specificity because of
nucleotide substitutions r esulting in amino
acid substitutions. O genes ar e inactive
because they cannot produce functional
enzymes.
Isolation of blood group A and B transferases has
been reported from several different sources including
human plasma (A transferase16–18 and B transferase19)
and porcine submaxillary glands (A transferase20,21).
Although tens to hundreds of thousands-fold
concentrations of enzyme activity were attained, the
fractions were not homogeneous. A protein that
appeared to be the soluble form of human A transferase
was purified to homogeneity from lung,22 gastric
mucosa,23 and plasma.24 The protein purified from lung
by Clausen et al.22 was a glycoprotein with a molecular
weight of ~ 40kDa but it lost its enzyme activity during
the last step of purification through reverse-column
chromatography. The protein and the trypsinized
peptides were later subjected to partial amino acid
sequence determination. The N-terminal 13 amino acid
sequence of the protein was identical to the sequence
of a protein purified from gastric mucosa by
Navaratnam et al.23
In collaboration with Clausen and Hakomori,
Yamamoto1 cloned cDNA encoding this protein that
seemed to be the soluble form of A transferase. The
partial amino acid sequence of a peptide was reverse-
translated into two degenerate oligo primer sequences.
PCR was performed to amplify genomic DNA and
cDNA fragments that were hybridized with a
radiolabeled oligo probe toward the internal sequence.
Using this cloned fragment as a radiolabeled probe,
MKN45 human stomach cancer cell line cDNA library
was screened. This cell line was chosen because the
cells expressed high activity of A transferase and large
amounts of A antigens. Several cDNA clones hybridized
with the probe were obtained. One of the cDNA
clones, FY59-5, apparently contained an entire coding
sequence. The cDNA predicted that it encoded a type
II transmembrane protein consisting of 353 amino
acids. Later it was found that alternative splicing had
occurred and that this cDNA clone was missing three
nucleotides and one amino acid at the splicing
junction. Therefore, it is now presumed that A1 and B
transferases consist of 354 amino acids.
Two options for demonstrating the identity of the
purified protein to be the soluble form of A transferase
were conceived: either to express the cloned cDNA
and detect the enzymatic activity/reaction products or
to correlate different nucleotide sequences to alleles.
Although the eukaryotic expression system had been
established and was available, the correlation approach
was taken because of the absence of information on
the ABO genotype of the MKN45 cell line. It was
believed that no activity or products would be
detected if the genotype was AO and the cDNA
represented the O allele. There were additional
concerns that the cDNA might not be the mature form
of mRNA and even more critically that the purified
protein was not A transferase. In order to obtain a
clear-cut answer, Yamamoto constructed 2 cDNA
libraries with RNAs from SW48 and SW948 human
colon cancer cell lines, which were derived from
individuals with AB and O blood groups, respectively,
and screened those libraries. If the purified protein
was a real A transferase, it was assumed that cDNA
clones from the SW48 cDNA library could be
categorized into two groups representing A and B
alleles based on the different nucleotide and amino
acid sequences. It was also assumed that the
nucleotide sequences of the cDNA clones, if any,
obtained from the SW948 cDNA library should have
nucleotide sequences that are different from either
group of cDNA clones from the SW48 cDNA library.
Results that confirmed both of those assumptions were
obtained.25 Two groups of cDNA clones that had
differences in seven nucleotides resulting in four amino
acid substitutions were recognized from the blood
group AB cDNA library. The cDNA clones from the
blood group O cDNA library were almost identical to
the sequence of one group of the cDNA clones from
the AB cDNA library, except that one nucleotide was
missing at the N-terminal side of the coding sequence.
The difference in the amino acid sequence explained
the difference in specificity between the A and B
transferases. The single nucleotide deletion, which is
located close to the amino terminal side of the coding
region, changed the frame of codons and produced
truncated proteins rather than large functional
enzymes, which explained the nonfunctionality of O
alleles.
Yamamoto screened two additional cDNA libraries
he constructed with RNAs from colon carcinoma cell
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lines SW1417 from a blood group B individual and
COLO205 with an O phenotype (the blood group of
the patient was unknown). He categorized cDNA
clones based on the differences in nucleotide
sequence. The cDNA clones from the blood group B
cDNA library were divided into two groups: one
identical to one of the two groups from the SW48
blood group AB cDNA library and the other identical to
the cDNA clones from the SW948 blood group O cDNA
library. The cDNA clones from the COLO205 had the
same single nucleotide deletion that was observed in
the cDNA clones from the SW948 cDNA library in
addition to several nucleotide substitutions. These
results not only confirmed the identity of the purified
protein to be A transferase, but also deciphered the
molecular genetic basis of the ABO system. The central
dogma of ABO was proved to be correct. The A and B
alleles at the ABO genetic locus encode functional A
and B transferases that have different amino acid
sequences, resulting in the different donor nucleotide-
sugar specificity between those enzymes. The O alleles
were inactive because they were unable to produce
functional transferases. Furthermore, the results of the
SW1417 cDNA clones clearly demonstrated that ABO
genotyping is possible. Yamamoto knew that the
SW1417 cell line was derived from a blood group B
individual but the ABO genotype (BB or BO) of that
individual was unknown. However, the experiments
showed that the patient’s genotype was BO, having one
B and one O allele each. Both the SW948 and
COLO205 cDNA clones contained the common single
nucleotide deletion, however, they differed in several
nucleotide sequences. The results raised the question
that there might be other mechanisms to nullify the
gene functions in O alleles. Because the cloning
experiments were done with cancer cell lines, it was
necessary to examine the genomic DNA of normal cells
to determine whether the same differences in
nucleotide sequence would be found. Taking
advantage of the presence of RFLP among the ABO
alleles he identified,Yamamoto analyzed the nucleotide
sequence polymorphism using genomic DNA prepared
from blood samples with predetermined blood
types and demonstrated that the differences he
observed are common in the general population. It
was concluded that (1) amino acid substitutions
between A and B transferases (arginine, glycine,
leucine, glycine in A transferase and glycine, serine,
methionine, and alanine in B transferase at codons 176,
235, 266, and 268) should be responsible for different
donor nucleotide-sugar specificity of these two
enzymes and (2) the O allele is nonfunctional because
the gene cannot produce functional glycosyltransferase
enzymes. These are the molecular genetic basis of the
ABO polymorphism (Table 2).
Mutations r esulting in amino acid
substitutions and alternative splicing can
explain some of the ABO subgroup
phenotypes.
The ABO gene was previously mapped on
chromosome 9 at q34.26 The gene organization was
determined byYamamoto et al.27 and by Bennett et al.28
in 1995. The ABO gene spans over 18 kilobases, and is
comprised of 7 coding exons. The majority of the
soluble form of the enzyme is encoded in the last two
coding exons, 6 and 7. Because many of the cDNA
clones contained unspliced introns, the partial
nucleotide sequences in introns neighboring exons 6
and 7 were available prior to the elucidation of the
entire gene organization. Making use of this
information on the intron sequences, Yamamoto and
collaborators determined the partial nucleotide and
deduced amino acid sequences in those two exons for
some of the subgroup alleles. They amplified DNA
fragments containing exon 6 and 7 sequences, cloned
into a plasmid vector, and determined the nucleotide
sequences. Because of the absence of cell lines with
known ABO subgroup phenotypes, genomic DNA from
blood samples of subgroups was used.
The A2 allele was characterized by the presence of
a single nucleotide deletion close to the C-terminal of
the coding sequence, resulting in the possession of an
Table 2. Molecular genetics of the ABO genes
 cDNA cloning of A transferase gene, cloning of B and O allelic
cDNAs, and elucidation of molecular genetic basis of the ABO
system
4 amino acid substitutions between A and B transferases (R, G, L, G in
A transferase and G, S, M, A in B transferase at codons 1 76, 235,
266, 268)
261 delG single nucleotide deletion in O allele coding region resulting
in codon frameshift and producing a truncated non-functional protein
 ABO genotyping
Restriction Fragment Length Polymorphism (RFLP)
Allele-specific PCR amplification
Discrimination of AA and AO genotypes and BB and BO genotypes
 Proof of the central dogma of ABO
A/B gene⇒ A/B transferase⇒ A/B antigen
 Identification of mutations in subgroup alleles (A2, Ax, B3), cis-AB
and B(A) alleles, and another type of O allele
94 alleles deposited in the ABO database (October 2003)
(http://www.bioc.aecom.yu.edu/bgmut/index.htm)
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additional 21 amino acid residues at the end.29
Yamamoto et al,30 in collaboration with Harris, Judd,
and Davenport, observed heterogeneity among A3 and
B3 alleles because not all of the genomic DNA clones
possessed the same mutations. A single nucleotide
substitution resulting in an amino acid substitution was
observed in an Ax allele.31 Yamamoto et al.32 examined
cis-AB and B(A) alleles of hereditary interest and found
that these alleles encode chimeric enzymes of A and B
transferases. In the course of characterization of
subgroup alleles, Yamamoto et al.33 identified another
type of O allele that lacked the single
nucleotide deletion but contained
nucleotide substitutions resulting in an
amino acid substitution at codon 268
that is critical for nucleotide-sugar
recognition. These alleles are listed in
Figure 2.
Since this discovery, the nucleo-
tide and deduced amino acid
sequences of additional subgroup
alleles have been reported. The
number of alleles deposited in the ABO
System section of the Blood Group
Antigen Gene Mutation (BGAGM)
Database (http://www. bioc.aecom.yu.
edu/bgmut/index.htm) has accrued to
more than 90. The BGAGM Database,
which was established and has been
maintained by Blumenfeld, covers
reported alleles of 24 different blood
group systems, including ABO and Rh,
and has provided useful information
on blood group polymorphism.34 In
addition to the A1, A2, A3, Ax, B, B3, O,
cis-AB, and B(A) alleles, the nucleotide
and deduced amino acid sequences of
Ael, Aw, Bel, and Bw alleles have also been
added to the database. Olsson et
al,35–40,42–44 Hansen,41 Ogasawara et
al,45–48 Roubinet et al,49,50 Seltsam et
al,51,52 Yu et al,53–55 Sun et al,56 andYip et
al.57–60 and their colleagues contributed
greatly to this addition of other
subgroup alleles (see the review by
Olsson and Chester44). As opposed to
the entire coding sequences of the
three major alleles determined by
cDNA cloning, most, if not all, of the
sequences determined from those
subgroup alleles were partial sequences of genomic
DNA. Furthermore, for most alleles it remains to be
experimentally demonstrated whether the identified
mutations are responsible for the altered activity of
subgroup transferases. A majority of the mutations are
nucleotide substitutions resulting in amino acid
substitutions or a single nucleotide deletion/insertion
and correlate well with the presence of specific
subgroup alleles. In addition to mutations in the
coding sequences,mutations in intron sequences were
also identified. Being located at the splicing junctions,
Fig. 2. Representative alleles at the ABO locus. Nucleotide and deduced amino acid
sequences are compared among a dozen ABO alleles whose sequences were determined
by Yamamoto and colleagues. The cis-AB and B(A) alleles are included in the A and B
alleles, respectively, because of higher relative sequence homology. The nucleotide
substitutions that result in amino acid substitutions are shown in bold type.∅= deletion
of nucleotide.
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some of these mutations seem to affect the maturation
of mRNA and be responsible for weaker expression of
the A/B antigen.55,56
Not all of the amino acid substitutions
between A and B transferases ar e necessary
to cause them to have differ ent sugar speci-
ficity. The enzymes with strong A and B
transferase activity were cr eated by genetic
engineer ing.
The identification of gene mutations and the
functionality of the mutations are different. Seven
nucleotide substitutions resulting in four amino acid
substitutions were identified between A (A1) and B
alleles by the cloning study.25 The three nucleotide
substitutions that did not result in amino acid
substitutions were silent and not involved in the
difference in specificity between the A and B
transferases. However, it was unclear whether all four
amino acid substitutions were necessary for a
difference in specificity. One, two, or three
substitutions could have been sufficient. To answer
this question,Yamamoto and Hakomori constructed A
and B transferase cDNA expression constructs and
transfected them to HeLa cancer cells of the uterus,
which express type H antigens on the cell surface.61
They detected the appearance of A and B antigens on
the surface of cells transfected with A and B transferase
cDNA expression constructs, respectively. They also
constructed a total of 14 A-B transferase chimeric
constructs with all possible combinations of the four
amino acid substitutions between A and B transferases.
The results showed the codon at 176 did not affect the
specificity of the enzyme (Table 3). The codon at 235
was influential and those at 266 and 268 were crucial
for the difference in specificity of the A and B
transferases. The chimeric constructs that possess
methionine of B at 266 and glycine of A at 268 were
shown to express enzymes with strong A and B
transferase activity, which was the first demonstration
that the specificity of glycosyltransferase could be
modified by genetic engineering. Yamamoto continued
functional analysis with mutations specific to A2, A3,
and B3 alleles using DNA transfection assays. He has
shown that the single nucleotide deletion in the A2
allele and the single missense mutations in the A3 and
B3 alleles that he identified were functionally important
mutations that decrease the activity of the enzymes
coded by those rare alleles.62
Yamamoto further studied the effects of the amino
acid residue at codon 268 on the specificity and
activity of the enzyme (Fig. 3A).63 He constructed 20
each of cDNA expression constructs with A and B
transferase backbones that possess any one of 20
amino acid residues at that position. DNA from those
constructs was transfected into HeLa cells and the cell
surface expression of A and B antigens was examined.
The same DNA was also transfected into COS1 SV40-
transformed African Green monkey kidney cells, and
the enzymatic activity of A and B transferases in cellular
extracts was analyzed. The results of the experiments
showed that the size and charge of the side group of
amino acid residue at codon 268 is crucial for the
specificity and activity of the enzyme (Fig. 3B). The
side groups of 20 amino acids are shown in Figure 3C.
For example, at codon 268, A transferase possesses
glycine that is the amino acid residue with the smallest
side group of hydrogen atom (-H). When this glycine
was replaced by alanine with a larger methyl group
(-CH3), the protein acquired the ability to transfer not
only a GalNAc but also a galactose. Probably, the
Table 3. Enzymology and evolution of the A and B transferases
 Identification of amino acid substitutions r esponsible for
differ ent nucleotide-sugar specificity between A and B
transferases
Codon 1 76 (R in A transferase and G in B transferase); not
impor tant
Codon 235 (G in A transferase and S in B transferase);
in fluential
Codons 266&268 (L&G in A transferase and M&A in B
transferase); crucial
 Successful modification of nucleotide-sugar substrate specificity
by genetic engineer ing
Several A-B transferase chimeras with both A and B transferase
activity
 Structural basis of differ ent donor nucleotide-sugar specificity
and activity using 40 in vitr o mutagenized amino acid
substitution constructs at codon 268
Size and charge of the side group are crucial for transferase activity
and nucleotide-sugar substrate specificity.
Not only codon 268 but also codon 266 is important.
 Animal ABO genes
Homologous sequences in chicken and mammals
Primates: Conserved amino acid substitutions corresponding to
codons 266 and 268 of human transferases, depending on the ABO
genotype (L and G in the A gene and M and A in the B gene,
respectively)
Mouse: Genomic organization is similar to human gene.
Prevalent murine gene is functional cis-AB gene.
Pig:O allele deficiency in porcine AO system is due to a major
deletion, and therefore,O gene activation in porcine organs/tissues
xenotransplanted into humans is unlikely.
 ABO gene evolution
Construction of evolutionary trees of the ABO genes and ABO gene
family
I M M U N O H E M A T O L O G Y, V O L U M E 2 0 , N U M B E R 1 , 2 0 0 4 11
Review:ABO blood group system
Fig. 3. Specificity of the A and B transferases. (A). The regions of the A and B transferases around codons 266 and 268 are schematically shown in
combination with the sugar portion of the appropriate nucleotide-sugars. (B). DNA transfection experiments of the in vitro mutagenized A and B
transferase constructs. The results of A and B antigen expression on the surface of the transfected HeLa cells and the results of the enzymatic assays
of the A and B transferases in the extracts of the transfected COS1 cells are shown. (C). The side groups of 20 amino acids with the chemical
formulas are shown. The nitrogen atom of the amino group is incorporated into a ring in proline, and therefore, the structure shown for proline
is not the structure of the side group.
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methyl group compensated for the smaller size of
hydroxyl group (-OH) of galactose than the N-acetyl
group (-NHCOCH3) of GalNAc at carbon 2 of the sugar
ring. When the glycine was replaced by serine
(-CH2OH) or cysteine (-CH2SH), the next smaller amino
acids, both A and B transferase activities were still
observed. When it was replaced by the slightly larger
threonine (-CH(OH)CH3) or asparagine (-CH2CONH2),
only B transferase activity was detected. The cavity for
sugar interaction might become too small for the
GalNAc entry. No other constructs expressed A or B
transferase activity other than the histidine and
phenylalanine constructs that exhibited weak A
transferase activity, which had no easy explanation.
Similarly, when the methyl group of alanine of the B
transferase is replaced by glycine, the smaller size of
hydrogen seems to permit the transfer of GalNAc in
addition to galactose. When the alanine was replaced
by amino acids with larger side groups, the activity
diminished as the size increased. Because the results
were different between constructs with the A
transferase backbone and those with the B transferase
backbone, the importance of other amino acid residues
between the two enzymes was recognized, especially
amino acid at codon 266.
Seto et al,64,65 in collaboration with Palcic and
Hindsgaul, expressed human A and B transferases and
their recombinants in E. coli and performed more
detailed enzymologic studies of those enzymes using a
variety of substrates. They reached similar conclusions
that the donor nucleotide-sugar specificity is attributed
to the amino acids at codons 266 and 268. Patenaude
et al,66 in collaboration with Palcic, determined the
three-dimensional structures of the human A and B
transferases and claimed that only codons 266 and 268
of the critical amino acid residues were positioned to
contact donor or acceptor substrates. In a more recent
paper, however, the importance of the region around
codon 235 for sugar specificity was acknowledged.67
They reached this conclusion from additional crystal X
ray diffraction studies of an enzyme coded by a novel
cis-AB allele that possesses a single point mutation that
replaced the conserved amino acid proline 234 with
serine in the B transferase backbone.
ABO genes ar e found in other species of
organisms.
ABH antigens were initially discovered in humans
on RBCs. However, substances with the same or similar
immunodominant structures were later found in a
variety of living organisms, including plants and
bacteria. Because human sera and plant lectins with
broad specificity were used in the early studies, the
chemical nature of many of those substances remains
to be determined. After cloning the cDNA encoding
human histo-blood group A transferase, Kominato et
al.68 examined the presence or absence of a homol-
ogous gene sequence by hybridizing human A
transferase cDNA probe with genomic DNA prepared
from other organisms. They observed weak hybrid-
ization with chicken DNA and strong hybridization
with mouse DNA, however, no hybridization was
detected with DNA from organisms that are located
lower in the phylogenetic evolutionary tree: bacteria,
yeast, nematode, clam, lobster, fly, sea urchin, and frog.
They also examined genomic DNA from other species
of mammals and observed hybridization with all the
species examined: dog, cat, rabbit, cow, sheep, rat,
hamster, and marmoset.
In the same paper,68 they reported their findings on
primate ABO genes. Bernstein’s model of inheritance
was known to apply to almost all primates. Depending
on their genotypes, Old and New World monkeys
express ABH substances in secretion.69,70 Whereas four
major phenotypes are known in humans, nonhuman
primates seem to have fewer phenotypes, depending
on the species. For example, only A and O phenotypes
are reported in chimpanzees and all gorillas seem to
have the B phenotype.
In anthropoid apes, chimpanzees and orangutans
express the antigens on their RBCs, but gorillas do not
have much expression of their B antigens. Further-
more,animals that do not produce the antigens possess
antibodies in serum, similar to humans. Therefore,
Landsteiner’s Law also applies to primates. Kominato
et al.68 determined the partial nucleotide sequences of
chimpanzee blood type A gene, gorilla B gene,
orangutan A gene,macaque A gene, and baboon A and
B genes. They found that the amino acid sequences
corresponding to human codons 266 and 268 are
conserved during evolution in these species (leucine
and glycine in A and methionine and alanine in B),
suggesting the importance of those two amino acid
residues for different sugar specificity between A and B
transferases. The results of this primate study of A and
B alleles were confirmed by Martinko et al.71
Kermarrec et al.72 found that human and nonhuman
primate O alleles are species-specific and result from
independent silencing mutations, establishing the basis
of the O allele deficiency in primates.72
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Recently,Yamamoto and Yamamoto elucidated the
molecular genetic basis of the porcine AO blood
system.73 As opposed to human O alleles, the pig O
allele was found to lack most of the structural gene
encoding for the enzyme. Yamamoto et al.74 studied the
mouse gene and discovered that the mouse gene is a
cis-AB gene that encodes an enzyme with both A and B
transferase activity. They also showed that this gene is
prevalent because all of the species and subspecies of
mice they examined contained the same amino acid
residues at positions critical for sugar specificity. The
rat gene homologous to the human ABO gene was
cloned by Cailleau-Thomas and Le Pendu75 and
separately by Iwamoto and Kobayashi.76 The rat gene
cloned from the BDIX strain of rat showed identical
gene organization to the human gene and was mapped
on the rat chromosome 3 at q11–12, a region
homologous to human 9q34.75 The cDNA encoded an
enzyme with A transferase activity. Although the same
enzyme exhibited weak B transferase activity in vitro, it
was suggested that A and B antigens cannot be
synthesized by alleles of the same gene in this rat
inbred strain because of differential tissue expression
of those antigens. Four cDNAs were cloned from a
Wistar rat, three that showed A transferase activity and
one that showed B transferase activity.76 Strangely,
however, the B antigen was not detected in any organs
studied in wild Wistar rats despite the fact that the
transcript from the ABO homologue with B transferase
activity was ubiquitously present.
Evolution of ABO genes and related genes
Based on the nucleotide and deduced amino acid
sequences of the primate ABO genes, Martinko and
Klein71 claimed that the critical substitutions differen-
tiating the A and B genes occurred before the
divergence of the lineage leading to humans, chimpan-
zees, gorillas, and orangutans. Saitou and Yamamoto77
constructed phylogenetic networks of human and
nonhuman primate ABO alleles and observed at least
three independent appearances of B alleles from the
ancestral A form (Fig. 4A). They suggested that some
kind of balancing selection might have been operating
at the ABO locus. The view of convergent evolution
over trans-species inheritance of ancestor alleles was
supported by the study of primate O alleles by
Kermarrec and Blancher.72
The ABO genes are polymorphic at the single
genetic locus, ABO, so it is reasonable to assume that
they are homologous. However, there are additional
sequences in the human genome that are highly
homologous to the ABO gene (Fig. 4B). These genes
constitute the ABO gene family. The presence of genes
from this family was initially recognized when the
cDNA encoding human A transferase was cloned and
sequenced. It became instantly evident61 that the
nucleotide and deduced amino acid sequences had
significant homology with previously cloned genes of
bovine78 and murine79 α1,3-galactosyltransferases.
These enzymes catalyze the transfer of a galactose to
synthesize the α-galactosyl epitope (Galα1-3Gal-). As
opposed to A and B transferases, α1,3-galactosyl-
transferases utilize the acceptor substrates lacking a
fucose linked to the galactose. Both the enzyme
activity and the α-galactosyl epitope exist in most
mammals except for humans, apes, and Old World
monkeys.80 These species instead possess the antibody
against the α-galactosyl epitope. Presence of this
antibody is the primary reason for acute rejection of
pig organ xenotransplanted to humans.81 The human
gene encoding the α1,3-galactosyltransferase was
shown to contain frameshift and nonsense
mutations.82,83 In addition to this nonfunctional α1,3-
galactosyltransferase pseudogene, another homologous
sequence was cloned from human genomic DNA and
named hgt4.84 This sequence was also shown to be a
nonfunctional pseudogene. Two additional genes have
been shown to have some homology with the ABO
genes: Forssman glycolipid synthase (FS) gene85 and
iGb3 synthase gene.86 Forssman glycolipid synthase is
UDP-GalNAc:globoside α1,3-N-acetyl-D-galactosaminyl-
transferase that synthesizes the Forssman glycolipid
antigen (GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glc-
Cer). iGb3 synthase is UDP-galactose: β-D-galactosyl-
1,4-glucosylceramide α1,3-galactosyltransferase and
directs the synthesis of isoglobo-glycosphingolipids
(Galα1-3Galβ1-4Glcβ1-Cer) by transferring a galactose
toward LacCer (Galβ1-4Glcβ1-Cer). The original cDNA
clones of those glycosyltransferases were from dog and
rat, respectively. A human FS cDNA was characterized,
revealing an 86 percent similarity with the canine FS
gene at the nucleotide and 83 percent of the predicted
amino acid sequences.87 However, no detectable FS
enzyme activity was detected upon transfection of
COS1 cells with the human FS cDNA, which explains
the absence of the FS antigen expression in humans
except in certain disease states, such as lung and
gastrointestinal tumors.88 As shown in Figure 4C, the
amino acid residues corresponding to codons 266 and
268 of the human A and B transferases are important in
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Fig. 4. Evolution of the ABO and related genes. (A). A phylogenetic tree of the ABO genes of primates. Three independent occurrences of A to B
transitions are shown in bold lines. (B). A phylogenetic tree of the ABO family of genes. The murine AB and porcine A genes cloned byYamamoto
are clustered with the human A gene, indicating that they are ABO genetic equivalents. (C). Comparison of the deduced amino acid sequences of
a variety of glycosyltransferases from the ABO gene family.
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specifying the donor nucleotide-sugars of the other
members of the ABO gene family of glycosyltransferases.
ABH antigen expression undergoes changes
dur ing development and differ entiation, as
well as car cinogenesis.
It has long been known that newborns express less
(25–50%) of the A/B antigens on RBCs than do adults.
ABH antigens are peripheral structures carried on a
variety of branched and unbranched core structures.
Because these antigens are produced by the enzymatic
reactions, the presence or absence of the acceptor
substrates affects the expression of the antigens.
Smaller quantities of branched structures partially
explain the lower expression of ABH antigens on fetal
RBCs. Similarly, the concentrations of nucleotide-sugar
substrates, such as UDP-GalNAc or UDP-galactose, also
influence the enzymatic reactions. There is also
competition among different glycosyltransferases for
the same substrates. In addition to these classes and
concentrations of acceptor substrates and donor
nucleotide-sugar substrates available for the enzymatic
reactions, the changes in expression of A/B antigens
can also result from changes on levels upstream. For
example, mutations in gene structure, transcription of
A/B transferase mRNA, post-transcriptional modifi-
cation of the mRNA, translation into A/B transferases,
post-translational modifications of the enzymes, and
translocation of enzymes into the Golgi apparatus all
alter the A/B antigen expression (Table 4). Here,
dynamic changes in the expression of ABH and related
antigens are discussed.
Szulman performed initiatory immunohistochem-
ical work and discovered the changes in the expression
of ABH antigens at different stages of human
development.89,90 The changes in ABH antigen
expression associated with cell migration and
maturation from the basal germinal layer to the surface
layer were reported by Oriol91 and Orntoft.92 Mandel et
al.93 reported a sequential appearance of precursor
peripheral core determinants in the germinal layer,
followed by an H antigen on the intermediate layers
and later by A and B antigens on the more superficial
layers of oral mucosa.
In addition to the physiological changes, ABH
antigen expression undergoes changes in pathologic
phenomena, most evident in carcinogenesis (see the
review article by Hakomori).94 A higher incidence of
duodenal ulcer in group O individuals and of stomach
cancer in group A individuals was reported from an
etiological study.95 Although different groups of
individuals exhibit different degrees of susceptibility to
diseases, the causality is still unclear. The most
frequently observed change of the ABH antigen
expression in cancer is the loss (or diminution) of
expression. Loss of A/B antigens was initially reported
in stomach cancer.96 The reduction of those antigens
was later found associated with the decrease in
transferase activity.97 On the contrary, in colon cancer
the appearance of A/B antigens was reported.98,99 In
normal distal colon, the ABH antigen expression
diminishes during development due to the reduced
activity of α1,2-fucosyltransferase to synthesize the H
antigen. It was suggested that the activation of the
gene encoding this enzyme led to the synthesis of the
H antigen that was transformed into A/B antigens by
the A/B transferases already present in the cells. This
provides an example of the very complex regulation of
A/B antigen synthesis. Lee et al.100 reported that the
expression of A antigen in non-small-cell lung
carcinomas in group A or AB patients is a favorable
prognostic factor. Miyake et al.101 reported that positive
immunostaining by MIA-15-5 antibody, which defines
H/Ley: Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-)/Leb anti-
gens,among blood group A or AB patients with primary
lung cancer is inversely correlated with survival. An
interesting phenomenon named “incompatible” A
antigen expression was discovered.102–104 The
phenomenon was named “incompatible” because they
observed the expression of A antigens in tumors of
group B and O patients that are not supposed to
express functional A transferase. Early immunohisto-
chemical studies used antibodies or lectins with broad
specificity, and, therefore, cross-reactions were
Table 4. ABO gene expression
 Regulatory mechanism of A/B antigen expression
Differ ent levels of control
Transcription, Post-transcription,Translation, Post-translation, Golgi
localization
Enzymatic reaction: substrate concentrations (both donor nucleotide-
sugars and acceptor H structures)
 Gene organization of the human ABO gene
Span over 18 kbp, 7 coding exons, CpG island in promoter
 Transcr iptional control
Promoter activity in the sequence just upstream of the transcription
initiation sites
Transcription factor Sp1 binding is required in both erythroid and
epithelial cell lineages.
An enhancer element is located further upstream.
Transcription factor CBF/NF-Y can bind to the enhancer element and
up-regulate gene expression in gastric cells.
Repression of expression by CpG island methylation
ABO gene transcription may be activated by demethylating agent
5-aza-dC.
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suspected with antigens of similar structures such as
Forssman antigen and Tn antigens (GalNAcα-Ser/Thr).
However, later studies confirmed the presence of
chemically defined A structure in the tumors from
blood group O patients105–107 and the presence of A
transferase activity.108,109 For example, David and
Clausen examined the expression of A transferase in 31
cases of gastric tumors of phenotype O by immuno-
histology on frozen sections using monoclonal
antibodies for the transferases. They found three
positive cases of which they confirmed the activity
using the extracts from the specimens. The A antigen
was also identified immunohistologically in these three
cases as well as in five other cases. However, the
chemical presence of A antigen was not confirmed by
thin-layer chromatography immunostaining analysis of
glycolipid extracts from the three positive cases. David
and Clausen speculated that incompatible A antigen
expression is a result of transferase expression derived
from the O gene by an undetermined mechanism.
In an effort to understand the molecular mech-
anisms of loss of A/B antigen expression, Meldgaard et
al.110 examined the ABO gene and its gene expression
in two immortalized human urothelial cell lines. They
found an intact A gene and A transferase mRNA, but
no activity of A transferase or expression of A antigen
on the cell surface. They later investigated the loss of
heterozygosity in bladder tumors that were negative
for A/B antigens and concluded that the loss of A/B
antigen expression was not due to the loss of the
transferase-producing functional allele or to the down-
regulation of ABO gene transcription.111 Instead, they
implicated a potential mechanism of post-translational
control to explain the disappearance of A/B antigens in
the bladder tumors.
Kominato, in collaboration with Yamamoto, took a
different approach and examined the promoter region
of the ABO gene,which controls the expression of the
gene.112 They first mapped and characterized the
promoter region by making nested deletion constructs
and examined the promoter activity of the genomic
DNA. In the promoter region they identified a CpG
island that is abundant in the CpG dinucleotide
sequence. Because CpG island methylation has often
been associated with inactivation of transcription,113,114
they proceeded to investigate the methylation status of
the CpG island of the ABO gene.115 DNA methylation
was found to be inversely correlated with gene
expression in the carcinoma cell lines they examined.
They also showed constitutive transcription of the
transiently transfected reporter plasmid containing the
ABO gene promoter regions in either expressor or
nonexpressor cells and that this transcription was
diminished by pretreatment of the plasmid with HhaI
methylase. Together with the fact that the treatment of
nonexpressor gastric cancer cell line MKN28 cells with
5-aza-2′-deoxycytidine, an inhibitor of DNA methyl-
ation, could have reactivated transcription, though
inefficiently, those results supported their contention
that DNA methylation may play an important role in
repressing the expression of the ABO gene. Iwamoto
et al.116 analyzed promoter methylation using genomic
DNA from A antigen positive and negative clones of
SW480 colon carcinoma cell line cells. They observed
the ABO gene promoter methylated in A antigen
negative clones,but unmethylated in A antigen positive
clones. Whether DNA methylation plays a negative
regulatory role in tumors, in addition to established cell
lines, remains to be examined.
Why does the ABO polymorphism exist?
What is the advantage?
Triggering the classical complement cascade,
mammalian C-type retroviruses are inactivated by
human serum.117 However, HIV,118 human T-cell
leukemia virus,119 and retroviruses that are produced in
human cells120 are resistant to inactivation by the
human complement. Because humans do not have a
functional α1,3-galactosyltransferase gene, but instead
contain the natural antibody against the α-galactosyl
epitope in sera, retrovirus inactivation mediated by
anti-α-galactosyl epitope natural antibody was
proposed.121,122
As opposed to this inhibition of interspecies
infection, a similar role of natural anti-A and anti-B
antibodies against intraspecies infection has been
proposed and examined. For example, HIV viruses
prepared from cultures of mixed PBMNCs from donors
of blood group A were neutralized by the monoclonal
antibody against A epitope, whereas the viruses
prepared from donors of blood group B or O were
not.123 Recently, Preece et al.124 addressed the same
question using the measles viruses: whether viral
particles can become glycosylated as determined by
the glycosylation status of the producer cell and as a
result be affected by human serum containing specific
natural antibodies. They prepared virus in HeLa cells
transfected with cDNA encoding, either human A
transferase, B transferase, an inactive truncated O
protein, or a porcine α1,3-galactosyltransferase. The
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viruses carried the same ABO structures as the cells: A
antigen if produced in type A cells and B antigen if
produced in type B cells. Only H antigen was detected
on the virus produced from type O cells, whereas
reduced amounts of H antigen appeared on the viral
particles prepared from type A and B cells. In addition,
the α-galactosyl epitope was transferred onto measles
viruses only when grown in human cells expressing
this structure. When those viruses were treated with
human preimmune sera, viral particles with type A, B,
and α-galactosyl epitopes were partially neutralized in
a complement-dependent manner. However, type O or
α-galactosyl epitope-negative viral particles were not
neutralized. They speculated that specific natural
antibodies mediated the neutralization because
synthetic A and Galα1-3Gal oligosaccharides
specifically blocked the inhibition.
Inoue, Matsumoto, and Yamamoto performed
similar experiments using amphotropic murine
leukemia virus (MLV). However, they observed signif-
icant loss of infectivity of the viruses after treatment
with sera irrespective of the ABO blood groups of sera
as well as the ABO phenotypes of the producer cells
(unpublished result). Because viruses were prepared
from HeLa cell transfectants of human origin, the
antibody against α-galactosyl epitope may not be
responsible for this inactivation. Although what caused
the drop in infectivity in those experiments remains to
be determined, seeking the biological function of the
ABO polymorphism in immunologic surveillance
seems to be reasonable as these polymorphic
oligosaccharides are exposed to, and potentially
involved in communication with, the outer world.
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